Twelve months Real-World Outcomes of Faricimab in Treatment-Naïve versus Previously Treated Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: visual outcome and macular morphological changes
This prospective study demonstrates that intravitreal Faricimab effectively improves visual and anatomical outcomes in both treatment-naïve and previously treated patients with nAMD and DME over 12 months, with naïve nAMD patients showing superior gains and fewer injections required compared to treatment-switched eyes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human eye relies on a delicate layer of tissue at the back called the retina to capture images and send them to the brain. When this tissue becomes damaged by age or disease, vision can fade permanently. Two of the most common causes of this vision loss are neovascular age-related macular degeneration and diabetic macular edema. In both conditions, the eye tries to heal itself by growing new, fragile blood vessels. Unfortunately, these new vessels leak fluid and blood, swelling the retina and blurring central vision. For years, the standard treatment has been to inject medicine directly into the eye to stop the growth signals that cause this leakage. While these injections work, they often require frequent visits to the clinic, and for some patients, the disease does not respond fully, leaving them with persistent swelling and vision loss.
Researchers have been searching for a better way to manage these leaks, one that might last longer between treatments and work for patients who have not responded to previous therapies. A new study from Egypt has examined the real-world performance of a newer medicine called faricimab. This drug works differently than older options by blocking two distinct pathways that drive fluid leakage, rather than just one. The study followed patients over a full year to see how well this dual-action approach restored vision and dried up the swelling in the retina. The researchers specifically compared two groups of people: those who had never received any eye injections before, and those who had tried other medicines for years without success and were now switching to faricimab.
The study initially enrolled ninety-seven patients with either age-related macular degeneration or diabetic macular edema. Every participant received three initial monthly injections to load the medicine into the eye. After this starting phase, the doctors monitored the eyes closely and adjusted the timing of future injections based on how the disease responded. The goal was to extend the time between shots as much as possible without letting the fluid return. Over the course of twelve months, the team measured how much vision improved and how much the swelling in the retina decreased. They also tracked how many injections each patient needed and whether the fluid completely disappeared from the eye.
The results showed that the new medicine worked well for everyone, but the experience differed depending on the patient's history. For patients with age-related macular degeneration who had never been treated before, the improvement was striking. These patients gained an average of nearly twenty-nine letters on a standard eye chart by the end of the year. Their retinas also shrank significantly, losing more than 260 micrometers of thickness, which indicates that the swelling had resolved. In contrast, patients with the same disease who had switched from other treatments saw more modest gains, averaging about twenty-two letters of improvement and a reduction in thickness of roughly 143 micrometers. Despite the difference in the size of the improvement, the patients who switched still saw their vision get better and their eyes dry out, proving that the medicine can help even after other treatments have failed.
For patients with diabetic macular edema, the story was slightly different. Both the new patients and those who switched from other drugs saw very similar results. Both groups gained about twenty to twenty-five letters of vision and saw their retinal thickness drop by over 200 micrometers. This suggests that for diabetic eye disease, the new medicine is equally effective whether it is the first treatment or the next step after others. A key finding across all groups was the rate at which the fluid completely disappeared. By the end of the year, more than three-quarters of the patients in every group had achieved a completely dry retina, with no fluid visible under the microscope. This high rate of success suggests the medicine is very good at stopping the leakage at its source.
Another important discovery concerned the burden of treatment. Patients who started with faricimab needed fewer injections over the year compared to those who switched from other medicines. The new patients with age-related macular degeneration received an average of 7.4 injections, while those who switched needed 8.8. Similarly, in the diabetic group, new patients needed 6.7 injections on average, compared to 8.4 for the switchers. This indicates that eyes that had not been subjected to years of frequent injections were easier to manage and could go longer between doses. The researchers noted that the patients who switched had often required injections every five or six weeks before the switch, suggesting their disease was more aggressive or resistant, which is why they needed more frequent care even with the new drug.
Throughout the entire year, the treatment was safe. No serious complications, such as infection or severe inflammation, were observed in any of the patients. The study confirms that this dual-action medicine is a powerful tool for restoring vision and drying out the retina. It offers a significant advantage for patients who have never been treated, providing rapid and substantial recovery with fewer clinic visits. For those who have struggled with other treatments, it offers a reliable way to improve vision and control swelling, even if they require slightly more frequent monitoring. The findings support the idea that targeting the two main causes of fluid leakage simultaneously provides a robust solution for these sight-threatening conditions, offering hope for better long-term outcomes in real-world clinical settings.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.